Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery
This study is looking at the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) for patients with metastatic epidural spinal cord compression (MESCC). MESCC is when cancer has spread to the spine and is pressing on the spinal cord. The study aims to see if this radiation treatment, Stereotactic Radiosurgery, can be given safely while keeping the risk of serious side effects to the spinal cord low. Researchers will also look at how well it controls pain, improves quality of life, and overall survival. You might be able to join if you are at least 18 years old and have spinal metastasis that is close to your spinal cord or cauda equina, as seen on an MRI. The study is currently recruiting about 60 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and any side effects will be monitored throughout the study, which is expected to last an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery
At a glance
Conditions
NCT06204315
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
MD Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Amol Ghia, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0